Why the study?
Does dienogest therapy increase the risk of subarachnoid haemorrhage in patients with risk factors?
Does dienogest therapy increase the risk of subarachnoid haemorrhage in patients with risk factors?
Answers are grounded in this paper and cite their sources.
Dienogest therapy may increase the risk of subarachnoid haemorrhage by inducing a hypoestrogenic state, highlighting the need to screen for cerebral aneurysm risk factors before initiation.
We present the third case of subarachnoid haemorrhage (SAH) during dienogest (DNG) therapy documented in Japan. A woman in her 40s with a history of smoking and a family history of SAH developed a sudden severe headache and was diagnosed with SAH. Angiography revealed a ruptured anterior communicating artery aneurysm (9.4 mm), which was successfully treated with a Woven EndoBridge. DNG induces a hypooestrogenic state, with serum oestradiol levels dropping to 30 pg/mL after 1 year, potentially increasing the risk of aneurysm rupture. We revised our protocol accordingly to screen for SAH risk factors and perform magnetic resonance angiography (MRA) on patients with a relevant family history. Among the 120 patients screened, 10 patients had a family history of SAH and underwent MRA, which led to the detection of one unruptured aneurysm. DNG therapy was subsequently discontinued. These findings underscore the importance of assessing cerebral aneurysm risk before initiating DNG therapy.
No takes yet. Share an insight, caveat, or question.
Kojima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: